Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 32,184,210
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 50,432 M
  • Annual Income, $ -2,762 M
  • EBIT $ 59 M
  • EBITDA $ 9,563 M
  • 60-Month Beta 0.84
  • Price/Sales 0.67
  • Price/Cash Flow 2.27
  • Price/Book 0.98
  • Price/Earnings ttm 5.93
  • Earnings Per Share ttm 1.35
  • Most Recent Earnings $0.17 on 11/12/25
  • Next Earnings Date 11/11/25
  • Annual Dividend & Yield 0.02 (0.28%)
  • Most Recent Dividend 0.023 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.15
  • Number of Estimates 1
  • High Estimate 0.15
  • Low Estimate 0.15
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -46.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.4790 +9.51%
on 11/04/25
8.6700 -5.54%
on 11/13/25
+0.3000 (+3.80%)
since 10/14/25
3-Month
7.4790 +9.51%
on 11/04/25
8.7000 -5.86%
on 10/01/25
+0.4700 (+6.09%)
since 08/14/25
52-Week
4.7900 +70.98%
on 12/24/24
8.7000 -5.86%
on 10/01/25
+2.7800 (+51.39%)
since 11/14/24

Most Recent Stories

More News
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
 KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

The investigational FINE-ONE trial met its primary endpoint, demonstrating that finerenone led to a significant reduction in urine albumin-to-creatinine ratio (UACR), an important marker of cardiovascular...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause 1 ...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause 1 ...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025

Bayer to unveil latest details on study design and baseline characteristics of the Phase III OCEANIC-STROKE study with asundexian Investigational agent asundexian is a once-daily, oral...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
Goldman Sachs Keeps Their Buy Rating on Bayer (0P6S)

Goldman Sachs analyst James Quigley maintained a Buy rating on Bayer today and set a price target of €34.50. The company’s shares closed yesterday at €27.48.Elevate Your Investing Strategy: Take...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest

Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm in the...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”

One A Day®, the multivitamin and supplement brand by Bayer rooted in 80+ years of nutritional science, today announced a bold new brand identity and positioning designed to better connect with today’s...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary clinical efficacy endpoints related...

BAYRY : 8.1900 (-4.77%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division

The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some of the...

BAYRY : 8.1900 (-4.77%)
IPG : 24.79 (-1.12%)
BAYZF : 32.8700 (-4.79%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 8.3433
2nd Resistance Point 8.2867
1st Resistance Point 8.2383
Last Price 8.1900
1st Support Level 8.1333
2nd Support Level 8.0767
3rd Support Level 8.0283

See More

52-Week High 8.7000
Last Price 8.1900
Fibonacci 61.8% 7.2064
Fibonacci 50% 6.7450
Fibonacci 38.2% 6.2836
52-Week Low 4.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar